Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Antibodies to Cytokine Protect Eyes During Bacterial Infection

By BiotechDaily International staff writers
Posted on 31 Oct 2012
Study shows improved pathology of bacterial eye infection upon topical treatment with polyclonal antibodies against the main neutrophil recruiting, proinflammatory cytokine; surprisingly, bacterial clearance was also improved.

Severe tissue damage during bacterial infections is often largely caused by inflammatory immune system by-products, noxious substances released from neutrophils attracted to the infection site to clear away the pathogen. As a key to attracting neutrophils, the proinflammatory cytokine interleukin-17 (IL-17) contributes to both microbial clearance as well as to inflammation-associated tissue damage.

A study led by researchers at Brigham and Women’s Hospital (Boston, MA, USA) investigated in vivo roles of IL-17 in mammalian eye infections using Pseudomonas aeruginosa to cause ulcerative keratitis after scratch injury in a mouse model. Two experimental approaches were used: examination of IL-17 receptor (IL-17R) deficient mice and testing of a topical treatment with polyclonal antibodies against IL-17. Pseudomonas aeruginosa was chosen mainly due to it being a common cause of corneal infections (particularly in those at higher risk such as extended-wear contact lens users) and as it is often found to be resistant to antibiotics.

The findings, published in the journal Infection and Immunity, October 2012, from both approaches showed that neutralization of IL-17 during P. aeruginosa corneal infection reduces neutrophil influx and pathology without compromising bacterial clearance. The antibody-mediated IL-17 neutralization approach was tested with six different laboratory or clinical P. aeruginosa strains, including both invasive and cytotoxic strains, all of which gave essentially the same results.

The strategy of inhibiting neutrophil tissue infiltration risked reducing the immune system’s bacteria-killing function - “We thought that blocking IL-17 infection might worsen eye infections,” said principal investigator Prof. Gregory P. Priebe of Brigham and Women’s Hospital and Boston Children’s Hospital, “Surprisingly, just the opposite was seen: blocking IL-17 with antibodies led both to fewer neutrophils in the eye, and to fewer bacteria.” The results therefore offer a new avenue for therapy of these sight-threatening infections.

Related Links:
Brigham and Women’s Hospital


Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.